earnings
confidence high
sentiment positive
materiality 0.65
Coherus Q1 LOQTORZI rev $11.8M (+61% YoY); net loss $36.9M; pipeline readouts mid-2026
Coherus Oncology, Inc.
2026-Q1 EPS
reported -$0.28
vs consensus -$0.28
▼ miss
(-0.4%)
- LOQTORZI net revenue $11.8M in Q1 2026, up 61% YoY from $7.3M but down 5% from Q4 2025 $12.4M due to weather and seasonality.
- GAAP net loss from continuing ops $36.9M ($(0.27) diluted EPS) vs $47.4M ($(0.41)) in Q1 2025; non-GAAP net loss $33.9M ($(0.25)).
- Cash, cash equivalents and marketable securities $167.0M; Q1 equity offering of 32.89M shares raised net proceeds of $53.6M.
- Casdozokitug Phase 2 1L HCC fully enrolled, first data readout expected mid-2026; tagmokitug combo studies with initial data mid-2026 and 2H 2026.
- Q1 recorded highest new patient starts for LOQTORZI; average treatment duration growing; LOQTORZI remains only FDA-approved treatment for NPC.